Lowering the affinity of single-chain monovalent BBB shuttle scFc-scFv8D3 prolongs its half-life and increases brain concentration
Monoclonal antibody therapeutics is a massively growing field. Progress in providing monoclonal antibody therapeutics to treat brain disorders is complicated, due to the impermeability of the blood-brain barrier (BBB) to large macromolecular structures. To date, the most successful approach for deli...
Główni autorzy: | , , , , , , |
---|---|
Format: | Artykuł |
Język: | English |
Wydane: |
Elsevier
2025-01-01
|
Seria: | Neurotherapeutics |
Hasła przedmiotowe: | |
Dostęp online: | http://www.sciencedirect.com/science/article/pii/S187874792400179X |